1	Quimioterapia	quimioterapia	NCFS000	C0392920#C0013216#C3665472	régimen/tratamiento#procedimiento	0-13	371(2)_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
2	adyuvante	adyuvante	AQ0CS0	C0001551	sustancia	14-23	371(2)_ANS_clinical_caseMIR	SENT1	I-Grp_Medicamento	-
3	en	en	SPS00	C1720294#C0332285	calificador#atributo	24-26	371(2)_ANS_clinical_caseMIR	SENT1	-	-
4	asociación	asociación	NCFS000	C0004083	atributo	27-37	371(2)_ANS_clinical_caseMIR	SENT1	-	-
5	con	con	SPS00	C0332287	atributo	38-41	371(2)_ANS_clinical_caseMIR	SENT1	-	-
6	el	el	DA0MS0	-	-	42-44	371(2)_ANS_clinical_caseMIR	SENT1	-	-
7	anticuerpo	anticuerpo	NCMS000	C0003250_1	sustancia_1	45-55	371(2)_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
8	monoclonal	monoclonal	AQ0CS0	C0003250_2	sustancia_2	56-66	371(2)_ANS_clinical_caseMIR	SENT1	I-Grp_Medicamento	-
9	trastuzumab	trastuzumab	NC00SC0	C0728747	sustancia#producto	67-78	371(2)_ANS_clinical_caseMIR	SENT1	I-Grp_Medicamento	-
10	,	,	Fc	-	-	78-79	371(2)_ANS_clinical_caseMIR	SENT1	-	-
11	seguida	seguir	VMP00SF	-	-	80-87	371(2)_ANS_clinical_caseMIR	SENT1	-	-
12	de	de	SPS00	C0332285	atributo	88-90	371(2)_ANS_clinical_caseMIR	SENT1	-	-
13	hormonoterapia	hormonoterapia	NC00SC0	C0279025	procedimiento	91-105	371(2)_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
14	.	.	Fp	-	-	106-107	371(2)_ANS_clinical_caseMIR	SENT1	-	-

